Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomas
Open accessAbstract
Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomasTo the editor Soft-tissue sarcomas (STS) represent a very heterogeneous group of rare tumors including more than 100 different subtypes [1].Surgery and neo/adjuvant radiation therapy represent the cornerstone of treatment for STS.However, despite an optimal resection of the tumor, up to 40% of patients will develop metastatic relapse and will die from the disease [1].Doxorubicin represents the first-line standard of care for patients with advanced disease since the 1970s, despite several attempts to identify better regimens.The median overall survival (OS) of patients with metastatic disease is < 18 months and has only modestly improved over the past 20 years [2].We and others have previously reported that nextgeneration sequencing (NGS) of tumor tissues allows the identification of genomic aberrations with the potential to influence and personalize therapy in up to 50% of patients with advanced STS [3,4].Genomic profiling of circulating tumor DNA (ctDNA) is increasingly used to tailor therapy in cancer patients.Indeed, such liquid biopsy has several advantages: noninvasiveness, reduced turnaround times for faster results, and the ability to fully capture the landscape of tumor heterogeneity [5].The aims of the present study were to investigate the impact of ctDNA profiling in a large cohort of patients with advanced STS included in two prospective precision medicine studies and to decipher the ctDNA molecular landscape of sarcoma.Between December 2020 and August 2021, 98 patients with advanced STS were included in two ongoing institutional molecular profiling studies (Bergonie Institute Profiling, BIP: NCT02534649; Gustave Roussy Profiling, STING: NCT04932525).Their character-
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Large-panel ctDNA sequencing may support precision profiling in advanced soft-tissue sarcoma, particularly when tissue biopsy is unavailable or when rapid molecular profiling is clinically relevant.
“Large-panel ctDNA sequencing may further support precision profiling in advanced soft-tissue sarcoma, particularly when tissue biopsy is unavailable or when rapid molecular profiling is clinically relevant [ 34 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [34]
Broad plasma panels, CNA-based WGS, methylation-based assays, cfRNA approaches, and CTC-based strategies remain more exploratory or proof-of-concept in most sarcoma subtypes, particularly when applied to low-volume MRD or routine surveillance settings.
“In contrast, broad plasma panels, CNA-based WGS, methylation-based assays, cfRNA approaches, and CTC-based strategies remain more exploratory or proof-of-concept in most sarcoma subtypes, particularly when applied to low-volume MRD or routine surveillance settings [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [34]
Commercial or large-panel plasma profiling may identify clinically relevant alterations in selected advanced cases.
“Commercial or large-panel plasma profiling may identify clinically relevant alterations in selected advanced cases, but variable tissue–plasma concordance, low tumor fraction, and inconsistent copy-number detection limit its use as a general surveillance strategy [ 32 , 33 , 34 , 35 , 36 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., González-Pérez, A., López-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 836 · see citing works
Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., Clark, T., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0237802 · Cited by 516 · see citing works
Chan, K. A., Jiang, P., Zheng, Y. W. L., Liao, G. J. W., Sun, H., Wong, J., Siu, S. S. N., Chan, W. C., Chan, S. L., Chan, A. T. �., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.196014 · Cited by 490 · see citing works
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V. L., Ferraro, R., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30496-0 · Cited by 214 · see citing works
Savina, M., Cesne, A. L., Blay, J., Ray-Coquard, I. L., Mir, O., Toulmonde, M., Cousin, S., Terrier, P., Ranchère‐Vince, D., Méeus, P., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0831-7 · Cited by 209 · see citing works
Self-citationShulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0212-9 · Cited by 149 · see citing works
Klega, K. S., Imamović, A., Ha, G., Clapp, A. N., Meyer, S. C., Ward, A., Clinton, C., Nag, A., Allen, E. M. V., Mullen, E. A., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00285 · Cited by 139 · see citing works
Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas
Lucchesi, C., Khalifa, E., Laizet, Y., Soubeyran, I., Mathoulin‐Pélissier, S., Chomienne, C., & Italiano, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0723 · Cited by 102 · see citing works
Self-citationSerrano, C., Vivancos, A. P., Pousa, A. L., Matito, J., Mancuso, F. M., Valverde, C. M., Quiroga, S., Landolfi, S., Castro, S., Dopazo, C., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6597-x · Cited by 54 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [1]WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed. Vol. 3).
Cited by
Sorted by citations
Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T. (2026) · Cells · doi:10.3390/cells15141271
- Authors
- Blanchi, J., Taleb, S., Bayle, A., Verret, B., Toulmonde, M., Spalato‐ceruso, M., Dubos, P., Laizet, Y., Alame, M., Khalifa, E., & Italiano, A.
- Affiliations
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Institut Bergonié (FR)
- Unité 1312, SARCOTARGET team
- Institut Bergonié
- Venue
- Cancer Communications
- Published
- 2023-07-05
- Volume
- 43
- Issue
- 9
- Pages
- 1051-1054
- ISSN
- 1000-467X (ISSN-L)
- 2523-3548
- PMC
- PMC10508143
- OpenAlex
- W4383217216
- Cited by
- 12
- References
- 9
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 1
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- 癌症：英文版 (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- MSD (Merck Sharp and Dohme) AVENIR (HEART)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- circulating tumor DNA, soft tissue sarcoma, liquid biopsy, next-generation sequencing, precision oncology, metastatic sarcoma, molecular profiling, doxorubicin, tumor heterogeneity, clinical utility
- MeSH terms
- Circulating Tumor DNA, Humans, Sarcoma, Soft Tissue Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
